New Zealand markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.16-0.35 (-5.38%)
At close: 04:00PM EST
6.16 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.51
Open6.55
Bid6.15 x 800
Ask6.70 x 800
Day's range6.08 - 6.60
52-week range6.08 - 24.30
Volume552,813
Avg. volume1,157,752
Market cap471.919M
Beta (5Y monthly)1.83
PE ratio (TTM)N/A
EPS (TTM)-1.97
Earnings date08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.14
  • Motley Fool

    3 Small-Cap Stocks to Buy Now and Hold for the Long Haul

    Looking for a way to hedge against runaway inflation? Small-cap stocks tied to nimble businesses that can quickly pivot during times of crisis are especially attractive at the moment. Since Oct. 27, 2021, the small-cap stock tracking Russell 2000 index is up 6.8%.

  • Business Wire

    Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

    BEDFORD, Mass., November 15, 2021--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

  • Business Wire

    Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

    BEDFORD, Mass., November 09, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made in June 2020 by t